

Figure S3. Comparison of *GAA* variants in IOPD patients treated with TLD-MTX with CRIM-positive IOPD patients treated with ERT monotherapy.





GAA, acid alpha glucosidase, IOPD, infantile-onset Pompe disease, TLD-MTX, transient low-dose methotrexate, CRIM, cross-reactive immunological material, ERT, enzyme replacement therapy.